Medexus Pharmaceuticals Inc (MDP) Price & Analysis

Compare

60 Followers

MDP Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.71 - C$5.56

Previous CloseN/A

Volume43.25K

Average Volume (3M)37.05K

Market Cap

C$84.19M

Enterprise ValueC$85.92M

Total Cash (Recent Filing)C$23.97M

Total Debt (Recent Filing)C$37.18M

Price to Earnings (P/E)20.3

Beta0.94

Next Earnings

Aug 12, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding32,258,354

10 Day Avg. Volume28,844

30 Day Avg. Volume37,051

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$5.75

Price Target Upside120.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Market DemandCanadian unit demand for Trecondyv grew 70% and the drug holds a significant market share in pediatric and adult alloHSCT markets in Canada.

Product LaunchPositive signs are seen in the launch of Grafapex.

Regulatory ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.

Bears Say

Product ProfitabilityManagement has decided to no longer sell Gleolan in the U.S. as the product was not profitable.

Regulatory ChallengesMedexus faces a negative Health Canada setback for Terbinafine.

Revenue DeclineTotal revenues decreased 4.6% year-over-year, a decline expected due mainly to generic pressure on Rupall.

Medexus Pharmaceuticals Inc News

Medexus Pharmaceuticals (MDP) Q1 Earnings Cheat Sheet

Medexus Pharmaceuticals (MDP) is scheduled to report 1st quarter earnings on 08/12/2025, after the market closes. Regarding Q1...

8h ago

Medexus Pharmaceuticals Announces First Fiscal Quarter 2026 Conference Call

An update from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals has scheduled a conference...

5d ago

Medexus Pharmaceuticals’ GRAFAPEX™ Receives NTAP Approval for 2026

The latest announcement is out from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ). Medexus Pharmaceuticals announced that GRAFAPEX™ (treosulfan)...

5d ago

Positive Outlook for Medexus Pharmaceuticals: Buy Rating Affirmed by Analyst

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc (MDP – Research...

1M ago

Medexus Pharmaceuticals’ Earnings Call Highlights GRAFAPEX Success

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q4 earnings call. Read on for the main highlights of the call....

1M ago

Medexus Pharmaceuticals Reports Strong FY 2025 Results and Successful GRAFAPEX Launch

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has shared an update. Medexus Pharmaceuticals reported strong fiscal year 2025 results,...

2M ago

MDP Upcoming Earnings Report: What to Expect?

Medexus Pharmaceuticals (MDP) is scheduled to report 4th quarter earnings on 06/25/2025, after the market closes. Regarding Q4...

2M ago

Medexus Pharmaceuticals Announces Fiscal Year 2025 Financial Results Conference Call

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has provided an announcement. Medexus Pharmaceuticals has announced a conference call scheduled...

2M ago

Medexus Secures Public Reimbursement for Trecondyv® in Quebec

An announcement from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals Inc. has successfully secured...

4M ago

Medexus Reports Strong Initial Uptake of GRAFAPEX™ in U.S. Market

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) just unveiled an update. Medexus Pharmaceuticals has reported a positive initial market...

4M ago

MDP FAQ

What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?

Medexus Pharmaceuticals Inc lowest stock price was C$1.71 and its highest was C$5.56 in the past 12 months.

What is Medexus Pharmaceuticals Inc’s market cap?

Medexus Pharmaceuticals Inc’s market cap is C$84.19M.

When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?

Medexus Pharmaceuticals Inc’s upcoming earnings report date is Aug 12, 2025 which is in 2 days.

How were Medexus Pharmaceuticals Inc’s earnings last quarter?

Medexus Pharmaceuticals Inc released its earnings results on Jun 25, 2025. The company reported -C$0.028 earnings per share for the quarter, beating the consensus estimate of -C$0.087 by C$0.059.

Is Medexus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medexus Pharmaceuticals Inc pay dividends?

Medexus Pharmaceuticals Inc does not currently pay dividends.

What is Medexus Pharmaceuticals Inc’s EPS estimate?

Medexus Pharmaceuticals Inc’s EPS estimate is -0.04.

How many shares outstanding does Medexus Pharmaceuticals Inc have?

Medexus Pharmaceuticals Inc has 32,258,354 shares outstanding.

What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?

Medexus Pharmaceuticals Inc reported an EPS of -C$0.028 in its last earnings report, beating expectations of -C$0.087. Following the earnings report the stock price went down -5.97%.

Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in TSE:MDP

Medexus Pharmaceuticals Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

5.27%

Trailing 12-Months

Asset Growth

17.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Medexus Pharmaceuticals Inc (MDP) Earnings & Revenues

Historic Earnings Reports

MDP Stock 12 Month Forecast

Average Price Target

C$5.75

▲(120.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","9":"C$9","2.25":"C$2.25","4.5":"C$4.5","6.75":"C$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$5.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,3.0707692307692307,3.4815384615384617,3.8923076923076927,4.303076923076923,4.713846153846154,5.124615384615385,5.535384615384616,5.946153846153846,6.356923076923077,6.7676923076923075,7.178461538461539,7.5892307692307694,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,2.897692307692308,3.1353846153846154,3.373076923076923,3.6107692307692307,3.848461538461539,4.086153846153846,4.323846153846154,4.561538461538461,4.799230769230769,5.0369230769230775,5.274615384615385,5.512307692307692,{"y":5.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,2.686153846153846,2.7123076923076925,2.7384615384615385,2.764615384615385,2.790769230769231,2.816923076923077,2.8430769230769233,2.8692307692307693,2.8953846153846152,2.9215384615384616,2.9476923076923076,2.973846153846154,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >